会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NOVEL GH-RH ANALOGS WITH POTENT AGONISTIC EFFECTS
    • 新的GH-RH模拟与POTENT激发效应
    • WO2013095903A1
    • 2013-06-27
    • PCT/US2012/067690
    • 2012-12-04
    • SCHALLY, Andrew, V.CAI, Ren-ZhiZARANDI, MartaUNIVERSITY OF MIAMIUNITED STATES OF AMERICA REPRESENTED BY THE DEPARMENT OF VETERANS AFFAIRS
    • SCHALLY, Andrew, V.CAI, Ren-ZhiZARANDI, Marta
    • C07K14/60A61K38/25
    • C07K14/60A61K38/00C07K14/61
    • The synthetic peptides have the sequence: [RrA\ A 2 , A 6 , A 8, A 11 , A 12 , A 15 , A 20 , A 21 , A 22 , Nle 27 , A 28 , A 29 , A30]hGH-RH(1 -30)-R 2 (SEQ ID NO: 1 ) wherein R 1 is Ac, Tfa, or is absent, A 1 is Tyr, Dat, or N-Me-Tyr, A 2 is Ala, D-Ala, Abu, or D-Abu, A 6 is Phe or Fpa5, A 8 is Asn, Ala, Gin, Thr, or N-Me-Ala, A 11 is Arg, His, or Har, A 12 is Orn, or Lys(Me)2, A 15 is Abu or Ala A 20 is Arg, His, or Har, A 21 is Orn, or Lys(Me)2, A 22 is Leu, or Orn, A 28 is Ser, or Asp, A 29 is Arg, Har, Agm, D-Arg, or D-Har, A 30 is Arg, Agm, Ada, Amc, Aha, Apa, Har, D-Arg, D-Har, Gab, Gin, D-GIn, Gin-Gab, D-Gln-Gab, or is absent, R 2 is -NH 2 , -OH, -NHR 2 , -N(R 2 ) 2 , or -OR 2 , in which R 2 is any of C 1-12 alkyl, C 2-12 alkenyl, or C 2-12 alkinyl, provided that if A 29 is Agm then A 30 and R 2 are absent A 1 is N-Me-Tyr only, and pharmaceutically acceptable salts thereof.
    • 合成肽具有以下序列:[RrA / A2,A6,A8,A11,A12,A15,A20,A21,A22,Nle27,A28,A29,A30] hGH-RH(1-30)-R2(SEQ ID NO :1)其中R1是Ac,Tfa或不存在,A1是Tyr,Dat或N-Me-Tyr,A2是Ala,D-Ala,Abu或D-Abu,A6是Phe或Fpa5,A8是 Asn,Ala,Gin,Thr或N-Me-Ala,A11是Arg,His或Har,A12是Orn或Lys(Me)2,A15是Abu或Ala A20是Arg,His或Har,A21 是Orn或Lys(Me)2,A22是Leu或Orn,A28是Ser或Asp,A29是Arg,Har,Agm,D-Arg或D-Har,A30是Arg,Agm,Ada,Amc ,Aha,Apa,Har,D-Arg,D-Har,Gab,Gin,D-Gln,Gin-Gab,D-Gln-Gab,或不存在,R 2是-NH 2,-OH,-NHR 2,-N (R2)2或-OR2,其中R2是C1-12烷基,C2-12烯基或C2-12炔基中的任何一个,条件是如果A29是Agm,则A30和R2不存在A1是N-Me-Tyr 仅及其药学上可接受的盐。